Company Profile

BLIS Technologies

A biotechnology company, BLIS commenced business in August 2000 when it acquired from the University of Otago, rights to Salivaricin B, a substance which acts as a natural antibiotic to control streptococcal throat infections. Since that time, it has acquired the University's collection of several thousand BLIS (bacteriocin-like-inhibitory substances) producing organisms collected over a 25-year period by Prof John Tagg, now a consultant to the company.


Announcements
Title Date Type
D&O Ongoing Disclosure Notice - Brian Watson Fri, Mar 25 2022 03:15 pm SHINTR
Third quarter performance update Fri, Feb 11 2022 08:30 am MKTUPDTE
Appointment of Marketing and eCommerce Director Thu, Feb 10 2022 02:39 pm ADMIN
Resignation of Marketing and eCommerce Director Wed, Dec 01 2021 12:14 pm ADMIN
Challenging market conditions in US impact half year result Thu, Nov 18 2021 08:43 am HALFYR
Half year results announcement date Tue, Nov 16 2021 01:39 pm GENERAL
New senior leadership role Fri, Oct 22 2021 03:02 pm ADMIN
Board of directors appointment Fri, Oct 22 2021 10:27 am ADMIN
Amended change of registered office Mon, Oct 04 2021 03:26 pm ADMIN
Change of registered office Mon, Oct 04 2021 02:55 pm ADMIN
Directors and Executives
Antony Balfour
Independent Director
Anthony P Offen
Independent Director
Geoff Plunket
Chair
Barry Richardson
Independent Director
Tom Ronnlund
Director
Dr Alison Stewart
Independent Director
Brian Watson
Chief Executive Officer
Richard Wingham
Chief Financial Officer
Company Details
Registered Office: Ground Floor, 442 Moray Place, Dunedin 9016
Postal Address: Ground Floor, 442 Moray Place, Dunedin 9016
Telephone: +64-347-41338
Facsimile: n/a
Website: http://www.blis.co.nz/
First Listed: 30/07/2001
Balance Date: 31 March
AGM: 21/07/2021
Major Holdings Announcements
Date Name No. Held % Current
07/07/21 Probi Aktiebolag 166,148,034 - 13.04
18/05/20 Wen Yi 53,280,077 5.83 4.81
27/03/18 W. Wu - 6.83 -
06/03/17 Edinburgh Equity Limited 31,157,388 5.59 2.81
08/02/17 Mingchun Qiu 39,000,000 5.50 3.52
Director’s Interests Announcements
Date Name No. Held % Details Other
25/03/22 Brian David Watson 4,730,431 - - -
09/03/20 Anthony Paul Offen 31,157,388 - - -
06/03/20 Alison Stewart 350,000 - - -
11/04/19 Geoffrey Phil Plunket 800,000 - - -
05/04/19 Alison Barrass 200,000 - - -
03/08/18 Barry Charles Richardso 17,903,625 - - -
01/12/16 Timothy James Mepham 55,977 0.01 - -
Analysts’ Forecasts
No forecasts available
Disclaimer
Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.
Last Updated: 01/02/2022
Opinion FREE
Brian Gaynor: a 'titan' of NZ's capital markets
Jenny Ruth | Sat, 21 May 2022

Brian Roche remembers Brian Gaynor as "sorta scary and impressive at the same time – a real 'conscience' of what was right and fair." 

On the Money
On the Money: Brian Gaynor tributes, Damien Grant's slip-up, Marsden Point and more
Pattrick Smellie | Sat, 21 May 2022

OTM this week: Tributes to a legend of the NZ investment world, who forgot to BCC their who's who subscriber list, a slightly bemusing no smoking note at the Budget lockup and more. 

Law & Regulation
Unlawful collection of Companies Office fees fixed under urgency
Ian Llewellyn | Fri, 20 May 2022

The Companies Office's administration of fees may have saved costs, but the problem is it was against the law.